• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IRX Therapeutics relocates creating 280 jobs in Florida

IRX Therapeutics relocates creating 280 jobs in Florida

October 21, 2011
CenterWatch Staff

St. Petersburg, Fla. - Gov. Rick Scott has reported the relocation of IRX Therapeutics, a clinical stage biotechnology company, to St. Petersburg from New York City by the year's end.  The company will staff more than 280 positions within five years at a projected minimum average wage of $90,000 annually.

"IRX's choice of Florida confirms that our state has set the stage successfully for a future that's rich in science, research and innovation," said Governor Rick Scott.  "I am pleased to support the company's continuing growth and job creation, which puts us one step closer to creating the jobs needed to get our state back to work."

IRX develops therapies to treat cancer and infectious diseases.  The company has raised $90 million to fund preclinical research, manufacturing and clinical development of IRX-2, a cancer treatment and IRX's chief product.  Initially, IRX will employ 40 people to begin a phase III trial.  The additional staff will work in commercial-scale manufacturing and expanded development functions in anticipation of a potential commercial product launch.

IRX's move actually marks its return to Florida and the Tampa Bay Region, where at the University of South Florida the company developed its technology.

To seal this business development prize for Florida, the state awarded IRX $600,000 from its Innovation Incentive Fund, which targets R&D catalyst projects.  Local provisions included $275,000 from Pinellas County, a $275,000 credit toward land owned by the City of St. Petersburg in the Dome Industrial Park (for future expansion), and $50,000 from the University of South Florida.  The Florida High Tech Corridor Council and Pinellas County Economic Development were also partner organizations in the economic development project.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing